Levetiracetam can be administered in addition to potassium bromide and phenobarbitone to further help in the reduction of seizure frequency and duration. The use of Levetiracetam is not associated with additional side effects and may help in cases of liver toxicity as the dose of KBr may be reduced as part of combination therapy.

A therapeutic range has not been established for the dog or cat but the human therapeutic range for Levetiracetam of 29 – 123 umol/L is considered appropriate. A steady state is not achieved with Levetiracetam, because accumulation does not occur. However the pharmacodynamic effect is believed to outlive the known half life. The risk of toxicity is believed to be low.

SERUM GEL TUBES MUST NOT BE USED FOR LEVETIRACETAM ANALYSIS